Evidence map›Paper›PMID 40332370›Full record

ArticleInternational journal of molecular sciences2025

Gene Expression Profile of Cultured Human Coronary Arterial Endothelial Cells Exposed to Serum from Chronic Kidney Disease Patients: Role of

Angélica Rangel-López, Minerva Mata-Rocha, Oscar Alberto Pérez-González, Ricardo López-Romero, Dulce María López-Sánchez, Sergio Juárez-Méndez, Vanessa Villegas-Ruiz, Alfonso Méndez-Tenorio, Juan Manuel Mejía-Araguré, Oscar Orihuela-Rodríguez and 7 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Angélica Rangel-LópezUnidad de Investigación Médica en Enfermedades Nefrológicas, UMAE Hospital de Especialidades, Centro Médico Nacional (CMN) Siglo XXI (SXXI), Instituto Mexicano del Seguro Social (IMSS), Mexico City 06720, Mexico.ORCID 0000-0001-7040-9379
Minerva Mata-RochaUnidad de Investigación Médica en Genética Humana, UMAE Hospital de Pediatría, CMN SXXI IMSS, Mexico City 06720, Mexico.
Oscar Alberto Pérez-GonzálezLaboratorio de Oncología Experimental, Instituto Nacional de Pediatría-SS, Mexico City 04530, Mexico.ORCID 0000-0002-5672-648X
Ricardo López-RomeroUnidad de Investigación en Biomedicina y Oncología Genómica, Hospital de Gineco-Pediatría 3A, IMSS, Mexico City 07760, Mexico.ORCID 0000-0002-5030-5836
Dulce María López-SánchezCentro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, SS, Mexico City 14080, Mexico.ORCID 0000-0002-7318-0618
Sergio Juárez-MéndezLaboratorio de Oncología Experimental, Instituto Nacional de Pediatría-SS, Mexico City 04530, Mexico.
Vanessa Villegas-RuizLaboratorio de Oncología Experimental, Instituto Nacional de Pediatría-SS, Mexico City 04530, Mexico.
Alfonso Méndez-TenorioLaboratorio de Biotecnología y Bioinformática Genómica, ENCB-Instituto Politécnico Nacional, Mexico City 11340, Mexico.ORCID 0000-0003-1871-4311
Juan Manuel Mejía-AraguréLaboratorio de Genómica Funcional del Cáncer, Instituto Nacional de Medicina Genómica, SS, Mexico City 14610, Mexico.ORCID 0000-0001-8027-6231
Oscar Orihuela-RodríguezDepartamento Clínico de Cardiología-UMAE Hospital de Especialidades, CMN SXXI IMSS, Mexico City 06720, Mexico.
Cleto Álvarez-AguilarFacultad de Ciencias Médicas y Biológicas "Dr. Ignacio Chávez", Universidad Michoacana de San Nicolas de Hidalgo, Morelia, Michoacán 58020, Mexico.ORCID 0000-0002-1608-1808
Abraham Majluf-CruzUnidad de Investigación Médica en Hemostasia, Trombosis y Aterogénesis, Hospital General Regional 1, IMSS, Mexico City 03103, Mexico.
Dante AmatoFacultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Mexico City 54090, Mexico.
Sergio Zavala-VegaLaboratorio Clínico y Banco de Sangre, Instituto Nacional de Neurología y Neurocirugía, SS, Mexico City 14269, Mexico.
Silvia Melchor-Doncel de la TorreLaboratorio de Virología, Unidad de Investigación en Enfermedades Infecciosas, Hospital Infantil de México Federico Gómez-Secretaría de Salud (SS), Mexico City 06720, Mexico.
Ramón Paniagua-SierraUnidad de Investigación Médica en Enfermedades Nefrológicas, UMAE Hospital de Especialidades, Centro Médico Nacional (CMN) Siglo XXI (SXXI), Instituto Mexicano del Seguro Social (IMSS), Mexico City 06720, Mexico.
José Arellano-GalindoLaboratorio de Virología, Unidad de Investigación en Enfermedades Infecciosas, Hospital Infantil de México Federico Gómez-Secretaría de Salud (SS), Mexico City 06720, Mexico.ORCID 0000-0001-7289-0821

Funding

Instituto Mexicano del Seguro Social and Direction of research at the Hospital Infantil de México Federico Gómez R-2008-3601-113/FIS/IMSS/PROT/551 and HIM/2021/068.
6 · The paper itself

Abstract

Patients with end-stage renal disease (ESRD) are at increased risk of cardiovascular disease (CVD), such as myocardial infarction (MI). Uremic toxins and endothelial dysfunction are central to this process. In this exploratory study, we used the Affymetrix GeneChip microarray to investigate the gene expression profile in uremic serum-induced human coronary arterial endothelial cells (HCAECs) from ESRD patients with and without MI (UWI and UWOI groups) as an approach to its underlying mechanism. We also explored which pathways are involved in this process. We found 100 differentially expressed genes (DEGs) among the conditions of interest by supervised principal component analysis and hierarchical cluster analysis. The expressions of four major DEGs were validated by quantitative RT-PCR. Pathway analysis and molecular network were used to analyze the interaction and expression patterns. Ten pathways were identified as the main enriched metabolic pathways according to the transcriptome profiling analysis, which were, among others, positive regulation of inflammatory response, positive regulation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) cascade, cardiac muscle cell development, highlighting positive regulation of mitogen-activated protein kinase (MAPK) activity (

Indexed as

Coronary VesselsEndothelial CellsMAP Kinase Signaling SystemRenal Insufficiency, ChronicTranscriptomeCells, CulturedFemaleGene Expression ProfilingGene Expression RegulationHumansMaleMiddle Agedchronic kidney diseaseendothelial cell dysfunctionend-stage renal diseasegene expression profilehuman coronary arterial endothelial cellsmicroarraysmyocardial infarctionuremiauremic toxins

Identifiers

PMID40332370
PMCPMC12027878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.